Por favor, use este identificador para citar o enlazar este ítem:https://uvadoc.uva.es/handle/10324/64723
Título
Stroke-Like Episodes and Cerebellar Syndrome in Phosphomannomutase Deficiency (PMM2-CDG): Evidence for Hypoglycosylation-Driven Channelopathy
Autor
Año del Documento
2018
Editorial
MDPI
Descripción
Producción Científica
Documento Fuente
International Journal of Molecular Sciences 2018. 2018 Feb 22;19(2). pii: E619
Abstract
Stroke-like episodes (SLE) occur in phosphomannomutase deficiency (PMM2-CDG),
and may complicate the course of channelopathies related to Familial Hemiplegic Migraine (FHM)
caused by mutations in CACNA1A (encoding CaV2.1 channel). The underlying pathomechanisms are
unknown. We analyze clinical variables to detect risk factors for SLE in a series of 43 PMM2-CDG
patients. We explore the hypothesis of abnormal CaV2.1 function due to aberrant N-glycosylation as a
potential novel pathomechanism of SLE and ataxia in PMM2-CDG by using whole-cell patch-clamp,
N-glycosylation blockade and mutagenesis. Nine SLE were identified. Neuroimages showed no
signs of stroke. Comparison of characteristics between SLE positive versus negative patients’ group
showed no differences. Acute and chronic phenotypes of patients with PMM2-CDG or CACNA1A
channelopathies show similarities. Hypoglycosylation of both CaV2.1 subunits (α1A and α2α)
induced gain-of-function effects on channel gating that mirrored those reported for pathogenic
CACNA1A mutations linked to FHM and ataxia. Unoccupied N-glycosylation site N283 at α1A
contributes to a gain-of-function by lessening CaV2.1 inactivation. Hypoglycosylation of the α2δ
subunit also participates in the gain-of-function effect by promoting voltage-dependent opening
of the CaV2.1 channel. CaV2.1 hypoglycosylation may cause ataxia and SLEs in PMM2-CDG
patients. Aberrant CaV2.1 N-glycosylation as a novel pathomechanism in PMM2-CDG opens new
therapeutic possibilities
Revisión por pares
SI
Patrocinador
This work was supported by national grant PI14/00021 and PI17/00101 from the National Plan on I+D+I, cofinanced by ISC-III (Subdirección General de Evaluación y Fomento de la Investigación Sanitaria), the Spanish Ministry of Economy and Competitiveness (Grants IPT-2012-0561-010000, SAF2015-69762-R, MDM-2014-0370 through the “María de Maeztu” Programme for Units of Excellence in R&D to “Departament de Ciències Experimentals i de la Salut”), FEDER (Fondo Europeo de Desarrollo Regional), and the Migraine Research Foundation (New York, USA). Mercè Izquierdo-Serra holds a “Juan de la Cierva-Formación” Fellowship funded by the Spanish Ministry of Economy and Competitiveness
Idioma
spa
Tipo de versión
info:eu-repo/semantics/publishedVersion
Derechos
openAccess
Collections
Files in this item
Except where otherwise noted, this item's license is described as Attribution-NonCommercial-NoDerivatives 4.0 Internacional